Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by
arterial and venous complications, progression to myelofibrosis, and transformation to acute …

Background We conducted a randomized comparison of hydroxyurea with anagrelide in the
treatment of essential thrombocythemia. Methods A total of 809 patients with essential …

Thrombotic, vascular, and bleeding complications are the most common causes of morbidity
and mortality in the Philadelphia chromosome–negative myeloproliferative neoplasms …

Myeloproliferative neoplasms are associated with increased risk for thrombotic
complications. These conditions most commonly involve somatic mutations in genes that …

Venous thromboembolism occurs commonly in patients with cancer. The pathogenetic
mechanisms of thrombosis involve a complex interaction between tumour cells, the …

Myeloproliferative neoplasms (MPNs), encompassing disorders like polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by …

In the last years, a growing amount of evidence has been produced regarding the role of
leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms …

Despite decades of clinical and laboratory research, relatively little has been accomplished
concerning the pathogenesis as well as the identification of risk factors for thrombosis and …

In polycythemia vera, vascular risk assessment is based on age and thrombotic history,
while the role of other potential predictors of this risk is still uncertain. Thus, we exploited the …